Revolution Medicines, Inc. Warrant Share Price
RVMDWRevolution Medicines, Inc. Warrant Stock Performance
Open $4.66 | Prev. Close $4.86 | Circuit Range N/A |
Day Range $4.66 - $4.93 | Year Range $0.07 - $6.12 | Volume 9,620 |
Average Traded $4.89 |
Revolution Medicines, Inc. Warrant Share Price Chart
About Revolution Medicines, Inc. Warrant
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Revolution Medicines, Inc. Warrant Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
29-Apr-26 | $4.86 | $4.86 | -5.63% |
28-Apr-26 | $4.83 | $5.15 | +24.40% |
27-Apr-26 | $4.14 | $4.14 | -3.72% |
23-Apr-26 | $4.27 | $4.30 | -12.51% |
22-Apr-26 | $5.01 | $4.92 | -9.48% |
21-Apr-26 | $5.25 | $5.43 | -3.72% |
20-Apr-26 | $5.60 | $5.64 | +6.02% |